Product Description
Interferon-gamma (IFN-?) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms.
Mechanisms of Action: IFNG Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bulgaria | Chile | Denmark | France | Germany | Greece | Hong Kong | Hungary | Ireland | Italy | Japan | Malta | Mexico | Netherlands | New Zealand | Norway | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | Spain | Sweden | Switzerland | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: InterMune
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Candidemia|Myelodysplastic Syndrome|Preleukemia
Phase 1: Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
alloSCT | P2 |
Recruiting |
Myelodysplastic Syndrome|Acute Myeloid Leukemia|Preleukemia |
2027-10-31 |
|
rIFN-Gamma 1b in Candidemia | P2 |
Active, not recruiting |
Candidemia |
2025-11-15 |
|
STUDY00002655 | P1 |
Recruiting |
Asthma |
2025-07-01 |